Inovio axes staffers, cancer program to 'sharpen focus,' save cash

A few months after AstraZeneca’s MedImmune unit walked away from some of its R&D work with the biotech, Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax on a bladder cancer test.